Regeneron Reports Third Quarter 2020 Financial and Operating Results
The Pharma Data
NOVEMBER 5, 2020
The FDA accepted for priority review, with a target action date of February 28, 2021 , the supplemental Biologics License Application (sBLA) for Libtayo ® (cemiplimab) as monotherapy to treat patients with first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) with ?50% Corporate and Business Development Update.
52 
Let's personalize your content